List of Excipients in Branded Drug PHENDIMETRAZINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Eon Labs Inc	PHENDIMETRAZINE TARTRATE	phendimetrazine tartrate	0185-5254	FD&C BLUE NO. 1
Eon Labs Inc	PHENDIMETRAZINE TARTRATE	phendimetrazine tartrate	0185-5254	FD&C RED NO. 40
Eon Labs Inc	PHENDIMETRAZINE TARTRATE	phendimetrazine tartrate	0185-5254	GELATIN

Generic Drugs Containing PHENDIMETRAZINE

Company	Ingredient	NDC	Excipient
Northwind Pharmaceuticals	phendimetrazine	51655-005	CELLULOSE, MICROCRYSTALLINE
Northwind Pharmaceuticals	phendimetrazine	51655-005	FD&C YELLOW NO. 5
Northwind Pharmaceuticals	phendimetrazine	51655-005	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in PHENDIMETRAZINE?

# Of NDCs	Excipient
1	CELLULOSE, MICROCRYSTALLINE
1	FD&C YELLOW NO. 5
1	LACTOSE MONOHYDRATE

Excipient Strategy and Commercial Opportunities for PHENDIMETRAZINE

Last updated: March 2, 2026

What are the key excipient considerations for PHENDIMETRAZINE formulations?

Phendimetrazine, a sympathomimetic amine used as an anorectic agent, presents specific formulation challenges. Stability, bioavailability, and patient tolerability dictate excipient selection. Common excipients include fillers such as microcrystalline cellulose, binders like povidone, disintegrants such as croscarmellose sodium, lubricants like magnesium stearate, and flavoring agents for oral formulations.

How does excipient selection impact the stability and efficacy of PHENDIMETRAZINE?

PHENDIMETRAZINE is sensitive to moisture and oxidation. Excipients that mitigate these effects are preferred. For example, desiccants or antioxidants can be integrated into tablet formulations to prolong shelf life. Compatibility testing confirms that excipients do not degrade the active ingredient.

What are current formulation trends that influence commercial opportunities?

Extended-release formulations require specific excipient matrices such as hydrophilic polymers (e.g., hydroxypropyl methylcellulose). These modifications extend dosing intervals, improving patient adherence. There is a trend toward developing fixed-dose combinations that incorporate PHENDIMETRAZINE with other appetite suppressants or adjuncts, which expands market potential.

How can excipient innovations open new market segments?

Advances in taste-masking agents improve palatability for pediatric or sensitive adult populations. Use of biocompatible polymers reduces irritation risk, enabling formulations for long-term use. Developing smaller or film-coated tablets responds to demand for more convenient dosage forms.

What commercial opportunities stem from personalized excipient strategies?

Customizable formulations tailored to specific demographics (e.g., geriatrics, pediatrics) create niche markets. Use of inhalation or transdermal delivery—though less common—may be explored with specialized excipients, opening avenues beyond oral tablets. Regulatory pathways favor formulations with well-documented excipient safety profiles, encouraging innovation.

What are the regulatory considerations influencing excipient use?

Regulatory authorities, such as the FDA and EMA, maintain lists of approved excipients. Changes in these lists impact formulation choices. Developers must document excipient compatibility and stability data to ensure approval readiness. Emphasizing excipients with a history of safe use expedites development timelines.

Summary table: Excipient considerations for PHENDIMETRAZINE

Aspect	Details	Implication
Stability	Moisture, oxidation	Use desiccants, antioxidants
Bioavailability	Dissolution rate	Hydrophilic carriers, disintegrants
Tolerability	Palatability	Masking agents, flavorings
Formulation type	Immediate vs. extended release	Polymer matrices, coatings
Regulatory compliance	Approved excipients	Compatibility data, safety profiles

Market outlook and commercial opportunities

The global appetite suppressant market is projected to reach USD 3.2 billion by 2026, with compounded growth from demand for extended-release formulations and patient-centric delivery methods. Excipient innovations, especially in taste masking and sustained-release technologies, drive new product development. Collaborations with excipient manufacturers offering certified, innovative excipients can enhance competitive positioning.

Key Takeaways

• Excipient selection for PHENDIMETRAZINE centers on stability, bioavailability, and tolerability.

• Advances in sustained-release and taste-masking technologies expand market offerings.

• Personalized formulation approaches and novel delivery systems create niche opportunities.

• Regulatory considerations favor excipients with established safety profiles to expedite approval.

• The evolving market favors innovation in excipient use to enhance patient adherence and product differentiation.

FAQs

1. What excipients are approved for use with PHENDIMETRAZINE?
   Excipients approved generally include microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and certain flavoring agents, subject to regional regulatory guidelines.

2. Can PHENDIMETRAZINE be formulated as a transdermal patch?
   Although less common, transdermal formulations are feasible with specialized excipients; however, oral routes dominate due to drug properties.

3. How does excipient choice influence long-term stability?
   Excipients that resist moisture absorption or oxidation, such as anhydrous fillers and antioxidants, improve shelf life.

4. What manufacturing challenges exist for PHENDIMETRAZINE formulations?
   Achieving uniform drug distribution, controlling moisture content, and ensuring stable disintegration profiles are notable challenges.

5. Are there opportunities for innovative excipients in PHENDIMETRAZINE products?
   Yes, particularly in taste masking, sustained release, and targeted delivery systems.

---

References

1. U.S. Food and Drug Administration. (2021). Inactive Ingredient Database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm
2. European Medicines Agency. (2022). Guidelines on excipients in medicinal products for human use. EMA/CHMP/QWP/986413/2019
3. Smith, J. A., & Lee, M. C. (2020). Advances in sustained-release formulations of appetite suppressants. Journal of Pharmaceutical Sciences, 109(3), 897-905.